Nkarta, Inc. (NKTX)

NMS – Цена в реальном времени. Валюта: USD

3.28

+0.10 (3.14%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.06

-0.22 (-6.78%)

После закрытия: May 12, 2026, 7:57 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Nkarta, Inc. (NKTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nkarta, Inc. (NKTX)

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

Nkarta to Participate in Evercore Healthcare Conference

Видео

No Data

Пресс-релизы

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Search stocks

Nkarta, Inc. (NKTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nkarta, Inc. (NKTX)

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

Nkarta to Participate in Evercore Healthcare Conference

Видео

No Data

Пресс-релизы

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights